R&D News | pharmaphorum

News

GSK licenses hepatitis B drug from J&J in $1bn deal

GSK has set its sights on dominance of the market for hepatitis B virus (HBV) therapeutics, licensing an antisense oligonucleotide drug from Arrowhead Pharma and Johnson &

News

Lilly buys Beam’s option on Verve drug programmes

Eli Lilly has agreed to buy a gene-editing programme for cardiovascular diseases from Beam Therapeutics in a deal, valued at up to $600 million, that ties in with the biot

News

Despite trial miss, Sarepta plans new filing for DMD therapy

Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy has failed to meet its primary objective in a phase 3 trial, but the company says it will file to extend

News

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in

News

Merck signs €1.4bn cancer alliance with China’s Hengrui

Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an

News

GSK claims a first with Jemperli in endometrial cancer

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

GSK licenses hepatitis B drug from J&J in $1bn deal

Lilly buys Beam’s option on Verve drug programmes

Despite trial miss, Sarepta plans new filing for DMD therapy

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Merck signs €1.4bn cancer alliance with China’s Hengrui

GSK claims a first with Jemperli in endometrial cancer

Sandoz says it is entering "golden decade" in biosimilars

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks